From the 2025 High Blood Pressure Guideline: At the point of maximum cuff oscillations, the BP in the cuff is equivalent to the mean BP in the artery, and SBP and DBP are estimated using proprietary manufacturer algorithms. For this reason, only oscillometric devices that were

🆕Se han presentado las nuevas guías de Hipertensión de la ACC/AHH. Las anteriores databan de 2017. Resumimos lo más relevante para práctica clínica. Descúbrelo en el siguiente enlace: 👇👇🏾👇🏻👇🏽 carprimaria.com/leer-ci/ht-hip…

“Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: diagnostic accuracy study.” Take a look at ESC Heart Failure👉 doi.org/10.1002/ehf2.1… #HFA_ESC #ESCHeartFailure EJHF Editor-in-Chief Jan Biegus @Ppponikowski Harriette Van Spall, MD MPH 🇨🇦 Shelley Zieroth

Resumen guías 2025 hiperaldosteronismo AMAREVA Riesgo Vascular Teresa Gijon Conde amareva.es/blog-post/guia…

Comentario de esther rubio sobre la Guía 2025 para el diagnóstico y tratamiento del hiperaldosteronismo primario: claves clínicas, interpretación hormonal y enfoque terapéutico amareva.es/blog-post/guia…

The 2025 High Blood Pressure Guideline has been released along with many accompanying articles. Check them all out today! Guideline: ahajrnls.org/4mhhrKg 2025 High Blood Pressure Guideline Journal Hub: ahajrnls.org/45l5Jsh

Madrid, epicentro de la cardiología a partir de este viernes y durante 4 días. Estas son parte de las controversias que podrían encontrar respuesta en este congreso. Descúbrelas a través de nuestro enlace 🔗👇🏻👇🏽👇👇🏾 carprimaria.com/leer-miscelane…

Just released‼️ 🚨2025 European Society of Cardiology #Guidelines on CVD & #Pregnancy! Endorsedby European Society of #Gynecology A must-read for all clinicians👇 #ESC2025 #CardioObstetrics #CardioTwitter #ESCCongress

Cardiac rehabilitation: the gateway for secondary prevention - heart.bmj.com/content/110/24…

🆕DAPA-CT HF-TIMI: ✅Es neutro a la hora de alcanzar el objetivo primario ( empeoramiento de IC y mortalidad CV. ✅Contribuye a demostrar el beneficio de los iSGLT2 ⬇️29% ☠️CV y 🏥IC @ICyFA-SEMI José Pérez Silvestre Alvaro Glez Franco Pau Llàcer Juan Carlos Obaya 👇🏼👇🏼 ahajournals.org/doi/pdf/10.116…

Presented at #ESCCongress: Among patients with myocardial infarction and a left ventricular ejection fraction of more than 40%, beta-blockers did not lead to a lower incidence of death, reinfarction, or hospitalization for heart failure than no beta-blocker therapy. Full REBOOT

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias academic.oup.com/eurheartj/arti…

Simultaneous publication during #ESCCongress Sex differences in the effect of beta blockers after myocardial infarction without reduced ejection fraction: A Pre-specified Analysis from the REBOOT Trial - ow.ly/geEN50WOx9w #EHJ

📌#Vericiguat and mortality in heart failure and reduced ejection fraction: the #VICTOR trial #ESC35 #ESCCongress

2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: integrating psychological well-being into cardiovascular care! academic.oup.com/eurheartj/adva… #mental #health #cardiovascular #risk #EHJ #Cardiotwitter #ESCCongress #guidelines @ESC_journals European Society of Cardiology

El fracaso en la lucha contra la hipertensión: no avisa, no duele, causa ictus, infartos, demencias y 46.000 muertes al año | Sociedad | EL PAÍS ⁦AMAREVA Riesgo Vascular⁩ ⁦SEH-LELHA⁩ elpais.com/sociedad/2025-…

#ECScongress #WCCardio. Hot line4: 🧬 KARDIA-3 trial: Zilebesiran = RNAi therapy that silences hepatic angiotensinogen → sustained RAAS suppression. 👥 In pts with uncontrolled HTN + CVD/high CV risk on multiple meds: 💉 Single dose (300/600 mg) ↓ office SBP by 5 & 3.3 mmHg vs

Original Article: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension (BaxHTN phase 3 trial) nej.md/4my7xUZ Editorial: Aldosterone Synthase Inhibition for Hypertension nej.md/4mtGZnz #ESCCongress | European Society of Cardiology

Presented at #ESCCongress: In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Full

🚨🫀 #ESC2025 en Madrid está dejando MUCHA tela que cortar. Aquí va un hilo 🧵 con lo más 🔝 para la práctica clínica (En cristiano, pero científico..) Spoiler: algunos estudios cambian lo que hacemos mañana en consulta 👇 (A los opositores MIR: esto NO entra❤️🫶😂)